Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters

G Fritz*,1, C Brachetti1, F Bahlmann2, M Schmidt2 and B Kaina1

1Institute of Toxicology, Division of Applied Toxicology, University of Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany; 2Department of Obstetrics and Gynecology, University of Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany

The present study addressed the question of a putative relevance of Rho proteins in tumour progression by analysing their expression on protein and mRNA level in breast tumours. We show that the level of RhoA, RhoB, Rac1 and Cdc42 protein is largely enhanced in all tumour samples analysed (n=15) as compared to normal tissues originating from the same individual. The same is true for 32P-ADP-ribosylation of Rho proteins which is catalysed by Clostridium botulinum exoenzyme C3. Also the amount of Rho-GDI and ERK2 as well as the level of overall 32P-GTP binding activity was tumour-specific elevated, yet to a lower extent than Rho proteins. Although the amount of Rho proteins was enhanced in tumours, most of them did not show changes in rho mRNA expression as compared to the corresponding normal tissue. Thus, elevated gene expression seems not to be the underlying mechanism of tumour-specific overexpression of Rho proteins. Sequence analysis of RhoA, RhoB, RhoC and Rac1 failed to detect any mutations in both the GTP-binding site and effector binding region. By analysing >50 tumour samples, the amount of RhoA-like proteins (i.e. RhoA, B, C), but not of Rac1, was found to significantly increase with histological grade and proliferation index. Rho protein expression was neither related to p53 nor to HER-2/neu oncogene status. Expression of rho mRNAs did not show a significant increase with histological grade. Overall the data show that (1) Rho proteins are overexpressed in breast tumours (2) overexpression is not regulated on the mRNA level (3) the expression level of RhoA-like proteins correlates with malignancy and (4) Rho proteins are not altered by mutation in breast tumours.

Keywords: Rho GTPases; breast tumours; tumour progression; mutation analysis

In the present study, we addressed the question of a putative relevance of Rho proteins in tumour progression by analysing their expression on protein and mRNA level in breast tumours. We show that the level of RhoA, RhoB, Rac1 and Cdc42 protein is largely enhanced in all tumour samples analysed (n=15) as compared to normal tissues originating from the same individual. The same is true for 32P-ADP-ribosylation of Rho proteins which is catalysed by Clostridium botulinum exoenzyme C3. Also the amount of Rho-GDI and ERK2 as well as the level of overall 32P-GTP binding activity was tumour-specific elevated, yet to a lower extent than Rho proteins. Although the amount of Rho proteins was enhanced in tumours, most of them did not show changes in rho mRNA expression as compared to the corresponding normal tissue. Thus, elevated gene expression seems not to be the underlying mechanism of tumour-specific overexpression of Rho proteins. Sequence analysis of RhoA, RhoB, RhoC and Rac1 failed to detect any mutations in both the GTP-binding site and effector binding region. By analysing >50 tumour samples, the amount of RhoA-like proteins (i.e. RhoA, B, C), but not of Rac1, was found to significantly increase with histological grade and proliferation index. Rho protein expression was neither related to p53 nor to HER-2/neu oncogene status. Expression of rho mRNAs did not show a significant increase with histological grade. Overall the data show that (1) Rho proteins are overexpressed in breast tumours (2) overexpression is not regulated on the mRNA level (3) the expression level of RhoA-like proteins correlates with malignancy and (4) Rho proteins are not altered by mutation in breast tumours.

British Journal of Cancer (2002) 87, 635 – 644. doi:10.1038/sj.bjc.6600510 www.bjcancer.com

© 2002 Cancer Research UK

Keywords: Rho GTPases; breast tumours; tumour progression; mutation analysis

The Ras homologous (=Rho) subfamily of low molecular mass (Mr ~21 kDa) GTP-binding proteins encompasses RhoA-like (e.g. RhoA, B, C), Rac and Cdc42 proteins. Among the Rho GTPases, specifically RhoA-like proteins have been shown to be ADP-ribosylated by exoenzyme C3 from Clostridium botulinum which leads to their inactivation (Aktories, 1997). Using this type of analysis as well as by microinjection of constitutively activated V14RhoA, the involvement of Rho proteins in the regulation of the organisation of the actin cytoskeleton has been demonstrated (Chardin et al, 1989; Paterson et al, 1990; Wiegers et al, 1991). Rho proteins are reported to be associated with various kinases such as protein kinase N (PKN) (Watanabe et al, 1996), phosphoinositide-kinase (Tolias et al, 1995) and Rho binding kinase (Rock) (Leung et al, 1995). The latter influences the actin cytoskeleton through phosphorylation of the myosin light chain (Amano et al, 1996).

Whereas RhoA is thought to interfere mainly with stress fibre formation, Rac and Cdc42 are believed to regulate the formation of lamellipodia and filopodia, respectively (Nobes and Hall, 1995; Hall, 1998). In addition to their interference with the microfilamental network, Rho GTPases participate in the regulation of endocytosis (Lamaze et al, 1996), cell cycle progression (Olson et al, 1995), differentiation (Fritz et al, 1994a), genotoxic stress-induced signalling (Cosso et al, 1995; Hill et al, 1995; Minden et al, 1995) and notably also malignant transformation. For example, transforming potency has been reported for RhoA (Avraham and Weinberg, 1989; Perona et al, 1993). Both RhoA and Rac as well as RhoB are essential for Ras-mediated transformation (Khosravi-Far et al, 1995; Prendergast et al, 1995; Qiu et al, 1995). Furthermore, Rho GTPases interfere with cadherin dependent cell-cell contacts as well as with integrin function (Laudanana et al, 1996; Schwartz et al, 1996; Braga et al, 1997). In addition, guanine exchange factors (GEFs) for Rho GTPases such as Dbl and Tiam exhibit oncogenic potency (Habets et al, 1994; Yaku et al, 1994; Michiels et al, 1995; van Leeuwen et al, 1995; Schwartz et al, 1996). As analysed in vivo by a mouse xenograft model system, it has been suggested that RhoA and RhoC play a central role in the process of invasion and metastasis (Imamura et al, 2000; Del Peso et al, 1997; Itoh et al, 1999; Yoshioka et al, 1999; Clark et al, 2000). As demonstrated by a chip-based method, RhoC is involved in mediating metastasis of both murine and human melanoma cell lines (Clark et al, 2000). Altogether, data available are indicative of a possible role of Rho GTPases in tumour development and progression (Price and Collard, 2001; Schmitz et al, 2000). Yet, studies on human tissues supporting this hypothesis are largely missing. It is well established that overexpression and activation of oncogenes or inactivation of tumour suppressor genes are related to tumour formation, and often they are used as prognostic markers (Bos, 1988; Anderson et al, 1992; Knudson, 1993). In particular, point mutations or amplification of members of the ras gene family have been found in a variety of human tumours...
Materials and Methods

Materials

Tissues were obtained from pathologically verified normal and tumorigenic breast tissue originating from the same patient. We also addressed the question of a putative correlation of particular Rho species with established prognostic breast tumour markers and investigated whether or not regulatory domains of Rho proteins are affected by mutations in tumours.

Preparation of tissue extracts

Frozen normal and tumorigenic tissues originating from the same patient were dissected with a microtome. Extraction of proteins from cut slices was done as described (Fritz et al., 1999 b). Soluble fraction was obtained by centrifugation (10 000 g, 4°C, 10 min). Protein determination was performed according to Bradford (Bradford, 1976). Extracts were frozen in liquid nitrogen and stored at −80°C.

ADP-ribosylation assay

32P-ADP-ribosylation with 25 μg of protein from cytosolic extracts was performed as described (Fritz et al., 1994 b). Reaction products were separated by SDS–PAGE. After Coomassie staining gels were dried and subjected to autoradiography. For quantitation, densitometrical analysis was performed. For calculation of relative level of ADP-ribosylation of tumours, ADP-ribosylation of extracts from the human breast carcinoma cell line MCF-7 (grown in DMEM +10% FCS) was set to 1.0.

Western blot analysis

For immunological detection of Rho proteins 30–50 μg of cytosolic proteins were separated by SDS–PAGE (12.5% gel). After wet-blotting to nitrocellulose, proteins bound to the membrane were stained with Ponceau S in order to confirm that identical amounts of protein have been transferred. Expression of Rho GTPases (i.e., RhoA, RhoB, Rac, Cdc42) and the Rho-regulatory protein Rho GDI was analysed using the corresponding Rho specific antibodies (Santa Cruz and BD Transduction Laboratories). For determination of RhoA-like proteins an antibody cross-reacting with RhoA, B and C was used (number R73920) (BD Transduction Laboratories). As confirmed by comparative analysis of a panel of tumour samples within the family of Rho-like GTPases (Fritz et al., 1995). As described previously, RhoA specific antibody (number sc-179; Santa Cruz) does not cross-hybridise with RhoB protein and the other way around (Fritz et al., 1999 a). After incubation with peroxidase coupled anti-rabbit IgG and anti-mouse IgG, respectively, proteins were visualised by chemiluminescence.

Analysis of rho mRNA expression

In order to analyse the expression of the diverse Rho species on the level of the mRNA, total RNA was isolated from breast tissue samples using the Quiagen RNA extraction kit (Quiagen, Hilden, Germany). One μg of RNA was used for semiquantitative RT–PCR analysis (Titan One tube PCR kit, Roche Diagnostics GmbH). The sequence of the primer pairs for specific amplification of rhoA, rhoB, rhoC, rac1, Ki-Ras and GDH were the following: rhoA, (582 bp PCR product): (1) 5′-ATGGCTGCCATCGGAAAGAA-3′ and (2) 5′-TCACAAAGAAGGCAAAGAG-3′; rhoB, (548 bp PCR product): (1) 5′-GCGTGCGCAAGATGCTC-3′ and (2) 5′-TCATACACCTTGAGCAGTT-3′; rhoC, (582 bp PCR product): (1) 5′-ATGGCTGAATCCGGAAAGAG-3′ and (2) 5′-TCGAGAAATGGAGACAGCCTC-3′; rac1, (448 bp PCR product): (1) 5′-CATCAAGGTGTTGGTGTTGG-3′ and (2) 5′-TTCAGCACAATCTCCATT-3′; Ki-Ras, (469 bp PCR product): (1) 5′-AGCCGTGTGTGCTGCTATG-3′ and (2) 5′-GAGAGGCCGGCTCGAAAATG-3′; GDH, (392 bp PCR product): (1) 5′-GTCTTCACCAACCATGGAAGGCT-3′ and (2) 5′-CATGCAAGTGGTGGCTTTC-3′. For specific amplification of rac1 splice variant rac1b (Jordan et al., 1999; Schneieler et al., 2000) the following two sets of primer pairs were used: (1) 5′-CATCAAGGTGTTGGTGTTGG-3′ and (2) 5′-GGAATGCTTGTTCTCTCT-3′ resulting in PCR product of 274 bp as well as (1) 5′-GCCAGAAAGCTGAGGAT-3′ and (2) 5′-TTACAACCAAACTCT-3′.
CCTTAG-3’ leading to an amplification product of 287 bp in length. Rac1b mRNA expression was analysed by nested PCR of the rac1 amplification reaction. For PCR amplification 30 cycles were performed (annealing condition: 55°C, 2 min). PCR products were separated onto 1.5% agarose gels and visualised by ethidium bromide staining. Quantitation of PCR products was performed by use of image analysis software (Multi-analyser; Bio-Rad Laboratories, CA, USA). Specificity of rho amplification products (i.e. rhoA, rhoB, rhoC) was confirmed by diagnostic restriction enzyme digests using enzymes specifically cutting a particular rho cDNA species. Relative rho mRNA expression was calculated by referring rho mRNA level to that of GDH or Ki-Ras mRNA level.

Sequence analysis

To investigate whether or not mutations of Rho GTPases do occur in human breast tumours, PCR products were subjected to automated sequencing (373A DNA Sequencer from ABI). To detect putative mutational changes in central regulatory domains of Rho proteins, we focused on sequencing nucleotides 1-285 (AA 1-95), covering the GTP-binding and effector binding domains of Rho GTPases.

RESULTS

To address the question of putative relevance of Rho proteins in human carcinogenesis and tumour progression, we compared the expression of Rho GTPases in tumours from breast with that of normal tissue originating from the same individual. As representative shown in Figure 1A for three pairs of non-malignant vs corresponding malignant tissues, RhoA, RhoB, Rac1 and Cdc42 are overexpressed on protein level in breast tumours. In normal tissue, the expression of these Rho proteins is hardly or even not detectable. The latter is true in particular for RhoA and RhoB. Because RhoC specific antibody is not available, we were unable to analyse the expression of this Rho species on the level of the protein. In contrast to Rho GTPases, the expression of the Rho regulatory factor Rho-GDI is easily detectable both in tumour and in the normal tissue. The same is true for ERK2. In Table 1, relative levels of expression of Rho proteins, Rho-GDI and ERK2 in 15 pairs of normal vs malignant tissue from the same patient are compiled. In addition to Western blot analysis, we examined the expression of Rho proteins by means of Clostridium botulinum C3-mediated 32P-ADP-ribosylation (Rubin et al, 1988; Aktories, 1997). In line with the Western blot data, extracts from breast tumours showed largely enhanced levels of ADP-ribosylation as compared with the normal tissues, which displayed only very faint amounts of ADP-ribosylated Rho proteins (Figure 2A). Since Rho GTPases belong to the family of Ras-related small GTP binding proteins, we wished to know whether small GTPases in general are overexpressed in tumours and whether this happens to a similar extent as for Rho proteins. To this end we analysed the overall GTP binding activity of normal and tumorigenic tissue by performing 32P-GTP overlay assays. These experiments revealed that the overall GTP binding activity, representing the expression level of the family of small GTPases as a whole, was enhanced in the tumours (Figure 2B). However, it is important to note that also in the non-malignant tissue 32P-GTP binding activity was clearly detectable. This is in contrast to Rho proteins. Overall, the data show that Rho GTPases are highly overexpressed on the level of the protein in breast tumours. Rho-GDI, ERK2 and the overall expression of 32P-GTP binding proteins is also enhanced in tumours, yet to a clearly lower level than Rho proteins are. Obviously, there is a preferential overexpression of Rho GTPases in breast tumours.

The high level of expression of Rho proteins in tumours raises the question as to the underlying mechanism. One possibility is that rho gene expression is elevated in tumours. Therefore, we investigated rho mRNA expression in normal tissues and tumours by use of semiquantitative RT–PCR analyses. Relative rho mRNA amounts were calculated by relating them to the level of GDH or Ki-ras mRNA. Surprisingly, the tremendous overexpression of Rho in tumours on the protein level (see Figure 1A) was not reflected at all on the level of the RNA (Figure 3A). We would like to note that the data representatively shown in Figure 3A and Figure 1A are obtained from the analysis of identical samples. As shown in Figure 3B, rho mRNA level in tumours was in most cases not different from that of the corresponding non-malignant tissue. As referred to either Ki-ras or GDH mRNA levels, about 50–70% of the tumours showed a similar rho mRNA expression as the normal counterpart of the same individual. Ten to twenty per cent of the tumours even showed a >50% reduction in rho mRNA level (i.e. rhoA and rac1). Only for rhoB and rhoC, about 30% of the tumours exhibited increase in mRNA levels (Figure 3B). Overall, the data clearly demonstrate that the highly elevated expression of Rho proteins in breast tumours is not due to an increase in rho gene expression. The interindividual variability in rho mRNA expression was rather large, both in normal and malignant tissues (~4–10-fold) (Figure 3C). With respect to rac1 a splice variant named rac1b was recently cloned both from colorectal and breast tumours (Jordan et al, 1999; Schnelzer et al, 2000). Therefore we additionally investigated mRNA expression of rac1b in normal vs malignant breast tissue. Rac1b contains a 57 bp insert as compared to rac1 (Jordan et al, 1999; Schnelzer et al, 2000). Since the rac1 primers used span the region of the rac1b extra exon, rac1b is co-amplified by the primer combination we have used for rac1 expression analysis, and therefore rac1b is occasionally detectable as a second slower migrating band (Figure 3D, right upper part). To enable a more sensitive detection of rac1b, we performed nested PCR reactions using two different sets of rac1b specific primer pairs (PC-A and PC-B) which result in rac1b specific amplification products of 274 and 287 bp in length, respectively (Figure 3D). Comparing normal breast tissue samples with the corresponding
Table 1 Relative expression level of Rho proteins and Rho-regulating factor Rho GDI in human breast tumours as compared to the normal tissue originating from the same patient.

| Factor analysed | No of samples analysed | Expression in normal tissues | Expression in tumours | Rel. expression in tumours |
|-----------------|------------------------|------------------------------|-----------------------|--------------------------|
| RhoA            | 15                     | nd                           | ++                    | +++                     |
| RhoB            | 15                     | nd                           | +                      | +++                     |
| Rac1            | 15                     | nd - 0                       | ++                    | ++                      |
| Cdc42           | 15                     | nd - 0                       | ++                    | ++                      |
| Rho-GDI         | 15                     | +                            | +                     | ++                      |
| ERK2            | 15                     | +                            | +                     | +                       |

*One sample means one pair of tumour together with the corresponding normal tissue from the same patient; nd=not detectable; 0=very low; +/low; ++=high. +++=50-fold overexpression in tumour as compared to the corresponding normal tissue. ++=up to 20-fold overexpression in tumour as compared to the corresponding normal tissue. +/2–5-fold overexpression in tumour as compared to the corresponding normal tissue.

Figure 2 Comparative analysis of C3-mediated 32P-ADP-ribosylation and 32P-GTP binding activity of Rho proteins in human breast tumours as compared to normal tissue. (A) 32P-ADP-ribosylation of Rho proteins in extracts from tumour and corresponding non-malignant tissue. Twenty-five μg of cytosolic protein was 32P-ADP-ribosylated by use of exoenzyme C3 from C. botulinum as described in Materials and Methods. Reaction products were separated by SDS–PAGE. Autoradiography was densitometrically analysed and relative 32P-ADP-ribosylation of tissue extracts was related to that of MCF-7 cells, which was set to 1.0. Autoradiography of a representative analysis of three sampled pairs is shown in the upper part of the figure. N, normal tissue; T, tumour. (B) Analysis of 32P-GTP binding activity of extracts from non-malignant and tumorigenic breast tissue. Thirty μg of protein was separated by SDS–PAGE (15% gels). After wet blotting to nitrocellulose and renaturation, 32P-GTP binding activity was analysed as described in Materials and Methods. Relative GTP binding activity of extracts from MCF-7 cells was set to 1.0. The autoradiogram of a representative analysis is shown in the upper part of the figure. N, normal tissue; T, tumour.

Rho GTPases in breast tumours

G Fritz et al

Oncogene and p53 status. For control we included Rac1 in these studies. As an internal reference for quantitation of the amount of Rho proteins we used ERK2, because this protein showed a rather low variability in tumours (see Figure 4A). Extensive analysis of more than 50 tumours revealed that only the relative level of RhoA-like proteins (Rho/ERK2) significantly increases with histological grading from grade I to grade II (P<0.05) up to grade III (P<0.001) (Figure 6A). In the case of Rac1, a significant increase in protein amount was only observed from grade I to grade II progression (P<0.05) but not to grade III. Cdc42 expression level was not significantly different between grade I and grade III tumours (data not shown). Similar data were obtained on the basis of the proliferation index of tumours as determined by quantitation of MIB (Ki-67) positive cells (Figure 6B). Whereas Rac1 protein level was not significantly related to proliferation, highly proliferative tumours (i.e. >20% MIB-1 positive cells) showed a significant increase in the level of RhoA-like proteins as compared to tumours with low proliferation index (i.e. MIB-1 <3%) (P<0.05). The relative amount of RhoA-like proteins was neither related to HER-2/neu oncoprotein nor p53 status of tumours (data not shown).

Since there was a particularly large variability in the expression of rhoB and rhoC mRNAs in tumours (see Figure 3C), and having in mind a previous report indicating that rhoC mRNA expression is related to malignancy of pancreas tumours (Suwa et al, 1998a), we also examined whether rhoB and rhoC mRNA expression is related to histological grading. Initial experiments indicated that both rhoB and rhoC mRNA expression as well as rac1 expression might vary between GI and GIII tumours, but not the expression of rhoA (Figure 8A). Yet, although the expres-
Rho GTPases in breast tumours
G Fritz et al

Figure 3  rho mRNA expression in tumorigenic and normal breast tissue. (A) Total RNA from tumorigenic and corresponding normal tissue from breast was analysed as to the expression of various rho mRNA species (i.e. rhoA, rhoB, rhoC, rac1) by RT–PCR analysis as described in Materials and Methods. As internal control expression of Ki-ras and GDH mRNA was determined. N, normal tissue; T, corresponding tumour. (B) Quantitative densitometrical analysis of relative rho mRNA expression in breast tumours vs normal tissue. Shown is the percentage of tumours showing similar, increased or reduced level of rho mRNA expression as compared to the corresponding normal tissue of the same individual. Relative expression of rho mRNA species was calculated by referring rho mRNA amount to that of either Ki-Ras (Ras) or GDH (GDH). Both types of internal reference markers gave the same results. (C) Interindividual variation in the relative expression of rho mRNAs (rho mRNA/GDH mRNA) in normal and tumorigenic tissues from breast. (D) The upper part of the figure shows the results of representative RT–PCR analyses of two different paired samples (normal tissue (N) vs tumorigenic tissue (T)) where rac1b is clearly detectable (right part) or not (left part) as a co-amplification product of the rac1 RT–PCR reaction (Rac1). 1, 2, indicates the position of rac1 and rac1b amplification product, respectively. For more specific and sensitive analysis of rac1b expression (Rac1b), nested PCR was performed using two different types of rac1b specific primer combinations as described in Materials and Methods (PC-A and PC-B). In the lower part of the figure the quantitative evaluation of the expression of rac1b in normal breast tissue vs the corresponding tumorigenic tissue from the same patient (n=11; paired samples) is shown. Please note that the samples representatively shown under A and D are different from each other.

Figure 3  rho mRNA expression in tumorigenic and normal breast tissue. (A) Total RNA from tumorigenic and corresponding normal tissue from breast was analysed as to the expression of various rho mRNA species (i.e. rhoA, rhoB, rhoC, rac1) by RT–PCR analysis as described in Materials and Methods. As internal control expression of Ki-ras and GDH mRNA was determined. N, normal tissue; T, corresponding tumour. (B) Quantitative densitometrical analysis of relative rho mRNA expression in breast tumours vs normal tissue. Shown is the percentage of tumours showing similar, increased or reduced level of rho mRNA expression as compared to the corresponding normal tissue of the same individual. Relative expression of rho mRNA species was calculated by referring rho mRNA amount to that of either Ki-Ras (Ras) or GDH (GDH). Both types of internal reference markers gave the same results. (C) Interindividual variation in the relative expression of rho mRNAs (rho mRNA/GDH mRNA) in normal and tumorigenic tissues from breast. (D) The upper part of the figure shows the results of representative RT–PCR analyses of two different paired samples (normal tissue (N) vs tumorigenic tissue (T)) where rac1b is clearly detectable (right part) or not (left part) as a co-amplification product of the rac1 RT–PCR reaction (Rac1). 1, 2, indicates the position of rac1 and rac1b amplification product, respectively. For more specific and sensitive analysis of rac1b expression (Rac1b), nested PCR was performed using two different types of rac1b specific primer combinations as described in Materials and Methods (PC-A and PC-B). In the lower part of the figure the quantitative evaluation of the expression of rac1b in normal breast tissue vs the corresponding tumorigenic tissue from the same patient (n=11; paired samples) is shown. Please note that the samples representatively shown under A and D are different from each other.

Ras proteins are frequently mutated in a variety of human tumours. Therefore, in order to obtain data on the relevance of the Ras-homologous GTPases in the formation and progression of breast carcinomas, we analysed Ras proteins as to mutational alterations in tumours. These analyses were performed by sequencing the rho RT–PCR products. We focused on sequencing nucleotides coding for amino acids 1–95, because within this region the GTP-binding and effector binding domain of Rho GTPases is localised. Overall, 9–11 tumours and three normal tissues were subjected to sequence analysis. Neither constitutive mutational activation of RhoA, B, C or Rac1 due to V14 mutation (and V12 for Rac1, respectively), nor any amino acid exchange in their effector binding domain was detectable (Table 2). Obviously, the regulatory domains of RhoA-like proteins and Rac1 are highly conserved and functional still intact in the malignant breast tissue.
DISCUSSION

Although Rho GTPases have been shown to be required for cellular functions associated with tumour progression and invasiveness (Schmitz et al, 2000; Price and Collard, 2001), studies supporting the role of Rho for carcinogenesis and tumour progression in patients with cancer are largely missing. In the present study we aimed at (1) analysing the expression of different members of the family of Rho GTPases in breast tumours, both on the level of the protein and the mRNA, (2) establishing whether a correlation between Rho expression and clinically established diagnostic and prognostic parameters does exist and, (3) investigating whether or not Rho GTPases are mutationally altered in tumours.

The data show that RhoA, Rac1 and Cdc42 proteins as well as the level of 32P-ADP-ribosylation are largely enhanced in malignant tissue from breast as compared with normal tissue originating from the same patient. Also the amount of RhoB, which has recently been described to interfere with cytostatic drug resistance by influencing apoptotic cell death (Fritz and Kaina, 2000; Liu et al, 2001), is enhanced in tumours. Moreover, the level of overall 32P-GTP binding activity as well as the amount of Rho-GDI protein is elevated in tumorigenic tissue, notably yet to a much lower extent than Rho proteins. In line with a previous report we also observed the level of ERK2 protein to be elevated in carcinomas as compared to the normal tissue (Sivaraman et al, 1997).

As we have shown here, within the group of tumours, ERK2 seems to be equally distributed. Since the non-malignant tissue also displayed clearly detectable amounts of Rho-GDI, ERK2 and GTP binding activity, but no or only marginal expression of Rho proteins, the data indicate that breast tumours differ from the corresponding normal tissue notably in the overexpression of Rho GTPases.
The finding of a large overexpression of Rho proteins in breast tumours raises the question as to the underlying mechanism, in particular whether this phenomena is due to increase in rho gene expression. Surprisingly, in most cases (50–70%) tumorigenic and corresponding normal tissue expressed very similar levels of rho mRNAs (i.e. rhoA, rhoB, rhoC, rac1). As compared to the normal tissue, about 10–30% of the tumours revealed either enhanced levels of rhoB and rhoC mRNA or even reduced levels of rhoA and rac1 mRNA. Recently rac1 mRNA expression was reported to be enhanced in malignant vs benign breast tissues (Schnelzer et al., 2000). One possible explanation for this discrepancy might be that, in contrast to the study mentioned, we have analysed paired tissue samples, i.e. non-malignant and tumorigenic tissue originating from the same individual. Furthermore, the tumour specific increase in rac1 mRNA expression reported in this study was rather low (i.e. ~50%) (Schnelzer et al., 2000) and does not reflect the large increase in Rac1 protein expression observed in the tumours. This fact again is in line with our own data. In addition, we show that expression of the rac1 splice variant rac1b, which was shown to be enhanced in colorectal tumours (Jordan et al., 1999), is not tumour-specific increased in breast tissue. Regarding rac1b, our data corroborate the study of

Figure 6  Rho protein expression correlates with histological grade and proliferation index of breast tumours. (A) Relative expression of RhoA-like and Rac1 proteins of breast tumours was calculated by referring the Rho protein amount to the level of ERK2 protein (RhoA/ERK2 and Rac/ERK2, respectively). Relative Rho protein expression was related to the histological grade of breast tumours. 1, 2 and 3; grade I, grade II and grade III. *, statistical significance as referred to grade I (*P<0.05; **P<0.001). (B) Relative RhoA and Rac1 protein expression (RhoA/ERK2; Rac/ERK2) of breast tumours was related to proliferation index (MIB-1) of the tumours. 1, 2, 3: <5%, <20%, >20% MIB-1 positive cells. *, statistical significance as referred to MIB-1 <5% (*P<0.05).

Figure 7  Rho protein expression is not related to HER-2/neu oncogene or p53 status of breast tumours. Relative expression of RhoA-like Rho GTPases was related to HER-2/neu oncogene and p53 status of the tumours. 0, negative for either HER-2/neu overexpression or p53 mutation; 1, positive for HER-2/neu overexpression or p53 mutation.

© 2002 Cancer Research UK
altogether our results strongly indicate that the drastic differences in Rho protein levels between malignant and non-malignant breast tissue are not due to changes in expression of the corresponding rho mRNAs. Thus, obviously, differences in gene expression do not account for the observed tumour specific increase in Rho proteins. We also analysed the stability of Rho proteins in the breast carcinoma cell line MCF-7 upon inhibition of protein synthesis by cycloheximide/anisomycin. These experiments showed no significant changes in Rho protein level up to 10 h after blockage of protein synthesis (data not shown). This indicates that Rho proteins are highly stable, undergoing a very slow turnover. Therefore, although we can not completely rule out the possibility that Rho proteins are rapidly degraded under in vivo conditions in normal breast tissue but not in tumours, it appears more likely that differences in protein stability are not responsible for the elevated level of Rho GTPases observed in breast tumours. We hypothesise that translational control mechanisms are involved in the upregulation of the amount of Rho protein in tumours.

The data also revealed broad interindividual variations in the expression of rho mRNAs both in normal and tumorigenic tissues. The same is true for Rho protein expression in tumours (in normal tissue Rho protein level was in general below the detection limit). In contrast to Rho GTPases, the interindividual variability in the expression of Rho-GDI and especially ERK2 protein was very low in the tumour fraction. That is why we used ERK2 protein as internal reference for calculating the relative amount of Rho protein (i.e. Rho protein level/ERK2 protein level). Correlating relative Rho protein expression with various clinical parameters we found that the level of RhoA-like GTPases significantly increases with histological grade as well as with the proliferation index (MIB-1) of the tumours. Interestingly, the expression of Rac1, which is discussed to be the Rho GTPase most important for cell–cell and cell–ECM adhesion (Price and Collard, 2001) as well as for lamellipodia formation (Hall, 1998) correlates with histological grading only in case of progression from grade I to grade II, but not to grade III. One possible interpretation of this finding is that Rac function might be important only during early steps in tumour progression, but not in later steps. It is also possible that Rac activity is modulated in tumours by changes in the activity of regulatory factors such as guanine exchange factors (GEFs). In this case, Rac protein levels would remain unchanged. Therefore, future studies addressing the question of expression level and activity of Rho-regulatory factors in breast tumours are required. A correlation between RhoA-like protein expression and the amount of the HER-2/neu

---

**Table 2** Mutational analysis of Rho in breast tumours. Sequence analysis of Rho GTPases in malignant and normal human breast tissues. Nucleotides encoding amino acids up to position 95 were subjected to sequence analysis. This region of Rho GTPases covers their GTP binding and effector binding domains

| Rho GTPase | Samples analysed (tumour/normal tissue) | Mutational changes detected* (tumour/normal tissue) |
|------------|----------------------------------------|---------------------------------------------------|
| RhoA       | 11/3                                  | 0/0                                               |
| RhoB       | 11/3                                  | 0/0                                               |
| RhoC       | 10/3                                  | 0/0                                               |
| Rac1       | 9/3                                   | 0/0                                               |

*Indicated are the amino acid exchanges as based on the corresponding Rho protein sequences published in Emb1 database.
oncogene or p53 mutation was not observed. The same is true for RhoA expression and hormone status of the tumours (data not shown). Summarising the data, a good correlation with clinically established tumour markers was observed with RhoA-like proteins but not with Rac1 and Cdc42. Although the amount of Rho proteins in tumours was not related to their mRNA levels, we analysed whether mRNA expression of particular rho mRNA species might be independently related to the histological grade of breast tumours. This correlation analysis was performed since (1) about 30% of the tumours investigated showed enhanced expression of rhoB and rhoC mRNA and (2) in a recent report it has been shown that rhoC mRNA expression is related to malignancy of pancreas carcinomas (Suwa et al, 1998b). Unfortunately, studies on the level of protein expression were not included in this report. Therefore the question remains whether or not the reported increase in rhoC mRNA is accompanied by elevation in the amount of Rho protein. For breast tumours we found that there was only a tendency in the expression of rhoB, rhoC and rac1 mRNA, but not of rhoA mRNA, to increase with grading. The tendency was most obvious for rhoC. However, because of the tremendous variability of rhoC mRNA expression in grade III tumours, a statistically significant correlation as found on the level of the protein expression was not observed. Thus, in contrast to pancreas carcinomas, rhoC mRNA expression level seems not to be an indicator of malignancy in breast tumours.

Since Ras is often either overexpressed or mutationally activated in a variety of human tumours, we wished to know whether the Ras-homologous GTPases are mutationally altered in breast tumours. Sequence analyses of the RhoA-like GTPases RhoA, RhoB and RhoC as well as of Rac1 failed to detect any mutations within the GTP binding or the effector binding domains of these Rho GTPases. Obviously, tumour associated changes in Rho-regulated functions are independent of mutational changes of Rho proteins itself. Rather, overexpression seems to be the predominant trait of activation of Rho signalling in breast tumours. Whether or not alterations in the activity of Rho-regulatory factors or Rho effector proteins such as Rho-kinase (ROK) or p21-associated kinases (PAK) do also occur in breast tumours will be subject of forthcoming studies.

In summary, we demonstrated that different types of Rho GTPases are highly overexpressed on protein but not on mRNA levels in breast tumours as compared to the normal tissue of the same individual. The data show at the first time that the amount of RhoA-like proteins but not of Rac1 and Cdc42, is related to clinically established prognostic breast tumour markers such as histological grade and proliferation index. A significant correlation between the expression of RhoA-like GTPases and histological grade was only observed on the protein, but not on the mRNA level. Overall, the data support the view that RhoA-like proteins are important factors involved in the development and progression of breast tumours and are of prognostic value. Moreover, the data may provide a platform for the development of novel tumour therapeutical strategies which are based on the inhibition of RhoA-like GTPases.

ACKNOWLEDGEMENTS

This work was supported by the Wilhelm Sander-Stiftung (AZ: 99.014.1).

REFERENCES

Aktories K (1997) Bacterial toxins that target Rho proteins. J Clin Invest 99: 827 – 829
Amano M, Ito M, Kimura F, Fukuta Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase), J Biol Chem 271: 20246 – 20249
Anderson M, Reynolds SH, You M, Maronpot RM (1992) Role of Proto-oncogene activation in carcinogenesis. Environm. Health Perspectives 98: 13 – 24
Avraham H, Weinberg RA (1989) Characterization and expression of the human rhoH12 gene product, Mol Cell Biol 9: 2058 – 2066
Bos JL (1988) The ras gene family and human carcinogenesis. Mut Res 195: 255 – 271
Bradford MM (1976) A rapid and sensitive method for the quantitation of mammalian G protein RhoC is ADP-ribosylated by Clostridium botulinum C3 exoenzyme. Eur J Biochem 72: 248 – 254
Braga VM, Machesky LM, Hall A, Hotchin NA (1997) The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts. J Cell Biol (137): 1421 – 1431
Chardin P, Boquet P, Madaule P, Popoff M, Rubin EJ, Gill DM (1989) The mammalian G protein RhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilament in Vero cells. EMBO J 8: 1087 – 1092
Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for Rho [see comments]. Nature 406: 523 – 535
Cosso AA, Chiariello M, Yu J-C, Zuydchoest D, van der Kammen RA, Stam JC, Berne A, Collard JG (1994) Identification of a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 77: 537 – 549
Fritz G, Just I, Wollenberg P, Aktories K (1994a) Differentiation-induced increase in Clostridium botulinum C3 exoenzyme-catalyzed ADP-ribosylation of the small GTP-binding protein Rho, Eur J Biochem 223: 909 – 916
Fritz G, Kaina B (2000) Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death, Biochem Biophys Res Commun 268: 784 – 789
Fritz G, Kaina B, Aktories K (1995) The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA-damaging treatments. J Biol Chem 270: 25172 – 25177
Fritz G, Lang P, Just I (1994b) Tissue-specific variations in the expression and regulation of the small GTP-binding protein Rho, Biochim Biophys Acta 1222: 331 – 338
Habets GG, Schoffles EH, Zuydchoest D, van der Kammen RA, Stam JC, Berne A, Collard JG (1994) Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 77: 537 – 549
Hall A (1998) Rho GTPases and the actin cytoskeleton, Science 279: 509 – 514
Hill CS, Wynne J, Treisman R (1995) The Rho family GTPases RhoA, Rac1 and CDC42Hs regulate transcriptional activation by SRF, Cell 81: 1159 – 1170
Imamura F, Mukai M, Ayaki M, Akedo H (2000) Y7-2632, an inhibitor of rho-associated protein kinase, suppresses tumour cell invasion via regulation of focal adhesion and focal adhesion kinase, Ipn J Cancer Res 91: 811 – 818
Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumour cells, Nat Med 5: 221 – 225
Jordan P, Brazao R, Boavida MG, Gespach C, Chastre E (1999) Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumours, Oncogene 8: 6835 – 6839
Khosravi-Far R, Solaki PA, Clark GF, Kinch MS, Der CJ (1999) Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15: 6443 – 6453
Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914 – 10921
Laudanna C, Campbell JJ, Butcher EC (1996) Role of Rho in chemoattraction.

Lamaze C, Chuang T, Terlecky LJ, Bokoch GM, Schmid SL (1996) Regulation of receptor-mediated endocytosis by Rho and Rac. Nature 382: 177–179

Laudanna C, Campbell JJ, Butcher EC (1996) Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. Science 271: 981–983

Leung T, Manser E, Tan L, Lim I (1995) A novel serine/threonine kinase binding the ras related rhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 270: 29051–29054

Liu A-X, Cerniglia GJ, Bernhard EJ, Prendergast GC (2001) RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. PNAS 98: 6192–6197

Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG (1995) A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375: 338–340

Minden A, Lin A, Claret FX, Abo A, Karin M (1995) Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147–1157

Noes C, Hall A (1995) Rho, Rac and Cdc42 GTpases regulate the assembly of multimolecular focal complexes associated with actin stress fibres, lamellipodia, and filopodia. Cell 81: 53–62

Olson MF, Ashworth A, Hall A (1995) An essential role for Rho, Rac and Cdc42 GTpases in cell cycle progression through G1. Science 269: 1270–1272

Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A (1990) Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol 110: 1001–1007

Perona R, Estepe P, Jimenez B, Ballestero RP, Ramon y Cajal S, Lacal JC (1993) Tumorigenic activity of rho genes from Aplysia californica. Oncogene 8: 1285–1292

Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Fukumoto M, Symons M (1995) Transformation by Rho and Rac GTpases: implications for tumour cell invasion. Cancer Biol 11: 167–173

Quin R-G, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for Rac in Ras transformation. Nature 374: 457–459

Rubin EJ, Gill M, Boquet P, Popoff MP (1988) Functional modification of a 21 kDa G-protein when ADP-ribosylated by the chaperone of Clostridium botulinum. Mol Cell Biol 8: 418–426

Schmitz AAP, Govek EE, Böttner B, Van Aelst L (2000) Rho GTpases: signaling, migration and invasion. Exp Cell Res 261: 1–12

Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard H, Harbeck N, Schmitt M, Lengyl E (2000) RhoC in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19: 3013–3020

Schwartz MA, Toksoz D, Khosravi-Far R (1996) Transformation by Rho exchange factor oncogenes is mediated by activation of an integrin-dependent pathway. EMBO J 15: 6525–6530

Schwartz MA, Toksoz D, Khosravi-Far R (1996) Transformation by Rho exchange factor oncogenes is mediated by activation of an integrin dependent pathway. EMBO J 15: 6525–6530

Sivaraman VS, Wang HY, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478–1483

Suwa H, Ohshio G, Imamura T, Watanabe G, Arita S, Imamura M, Narumiya S, Hiai H, Fukumoto M (1998a) Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77: 147–152

Suwa H, Ohshio G, Imamura T, Watanabe G, Arita S, Imamura M, Narumiya S, Hiai H, Fukumoto M (1998b) Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77: 147–152

Tolias KF, Cantley LC, Carpenter CL (1995) Rho family GTpases bind to phosphoinositide kinases. J Biol Chem 270: 17656–17659

van Leeuwen FN, van der Kammen RA, Habets GG, Collard JG (1995) Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene 11: 2215–2221

Watanabe G, Saito Y, MadThu P, Ishizaki T, Fujisawa K, Morii N, Mukai H, Ono Y, Kakinaka A, Narumiya S (1996) Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTpase Rho. Science 271: 645–648

Wiegers W, Just I, Müller HM, Hellwig A, Traub P, Aktories K (1991) Alteration in the cytoskeleton of mammalian cells cultured in vitro by Clostridium botulinum C2 toxin and C3 ADP-ribosyltransferase. Eur J Cell Biol 54: 237–245

Yaku H, Sasaki T, Takai Y (1994) The Dbl oncogene product as a GDP/GTP exchange protein for the Rho family: its properties in comparison with those of Smg GDS. Biochim Biophys Res Commun 198: 811–817

Yoshio S, Nakamori S, Itoh K (1999) Overexpression of small GTpase-binding protein RhoA promotes invasion of tumour cells. Cancer Res 59: 2004–2010